Linaprazan Explained

Legal Status:	Investigational
Cas Number:	248919-64-4
Pubchem:	9951066
Unii:	E0OU4SC8DP
Synonyms:	AZD-0865
Iupac Name:	8-[(2,6-Dimethylphenyl)methylamino]-N-(2-hydroxyethyl)-2,3-dimethylimidazo[1,2-''a'']pyridine-6-carboxamide
C:	21
H:	26
N:	4
O:	2

Linaprazan is an experimental drug for the treatment of gastroesophageal reflux disease (GERD). Unlike the proton-pump inhibitors (PPIs) which are typically used to treat GERD, linaprazan is a potassium-competitive acid blocker (P-CAB).^{[1] [2]} Linaprazan was developed by AstraZeneca, but it was not successful in clinical trials.^[3]

The drug was then licensed to Cinclus Pharma,^[4] which is now investigating linaprazan glurate, a prodrug of linaprazan which is expected to have a longer biological half-life than linaprazan itself.^[4]

Notes and References

1. Rawla P, Sunkara T, Ofosu A, Gaduputi V . Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors? . World Journal of Gastrointestinal Pharmacology and Therapeutics . 9 . 7 . 63–68 . December 2018 . 30595950 . 6305499 . 10.4292/wjgpt.v9.i7.63 . free .
2. Web site: Linaprazan . Inxight Drugs . National Center for Advancing Translational Sciences .
3. News: Can reformulation of an AstraZeneca castoff rival Takeda's new heartburn drug? Here's a $26M bet on yes . Tong A . 4 March 2020 . endpts.com .
4. Web site: Linaprazan glurate . Cinclus Pharma .